SCHEMBL30795437

SCHEMBL30795437

O=C(Cc1cc(F)cc(F)c1)Nn1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ADRA1A P35348 5/20 0.45
▸ HRH1 P35367 5/20 0.45
▸ ADRA1B P35368 5/20 0.45
▸ HRH3 Q9Y5N1 3/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ EGFR P00533 1/20 0.43
▸ KDR P35968 1/20 0.43
▸ USP2 O75604 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ ABCB1 P08183 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1789505 1.00 ADRA1A (0.45) ADRA1AHRH1ADRA1BHRH3KDM4E
SCHEMBL1791416 0.92 TSHR (0.50) ADRA1AHRH1ADRA1BHRH3USP2
SCHEMBL30796305 0.92 TSHR (0.50) ADRA1AHRH1ADRA1BHRH3USP2
SCHEMBL30795062 0.90 ADRA1A (0.51) ADRA1AHRH1ADRA1BHRH3KDM4E
SCHEMBL1790428 0.90 ADRA1A (0.51) ADRA1AHRH1ADRA1BHRH3KDM4E
SCHEMBL13721196 0.88 MAPT (0.41) USP2LMNASMN1; SMN2TSHRMAPT
SCHEMBL30796387 0.88 TSHR (0.51) ADRA1AHRH1ADRA1BHRH3KDM4E
SCHEMBL1788819 0.88 TSHR (0.51) ADRA1AHRH1ADRA1BHRH3KDM4E
SCHEMBL30794712 0.84 LMNA (0.47) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL1789074 0.84 LMNA (0.47) LMNAALDH1A1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 — — EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 — — EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 — — WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 — — WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 — — WO disclosed
Send feedback